Background
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support for patients with cardiac failure [
1,
2]. Because ECMO is invasive, analgesia and sedation are important to limit responsiveness, prevent accidental decannulation, and maintain ECMO flows, all of which promote recovery [
3‐
5]. The use of opioids is standard practice during ECMO [
6‐
8].
Sufentanil is a synthetic opioid drug, which has a rapid onset and is 5–10 times more potent than fentanyl [
9]. It is highly protein bound (91–93%) [
10], metabolised by the liver, and excreted as metabolites in the urine (2% unchanged, 80% metabolites) [
11]. A large variability in sufentanil pharmacokinetics (PK) is expected in ECMO patients due to the combination of ECMO, drug characteristics, and disease factors [
12]. Volume of distribution (Vd) is altered owing to physiologic changes related to critical illness, hemodilution, and sequestration in ECMO circuit, while clearance (CL) is variable owing to organ dysfunction and non-pulsatile flow in VA-ECMO [
13‐
15]. ECMO could act as a reservoir that prolongs the effect of sedatives even after the drugs have been discontinued [
16]. Despite the widespread use of ECMO, the literature regarding sufentanil PK and ECMO was based on only in vitro analysis, which showed 83% loss of sufentanil in ECMO circuits at 24 h [
17]. In the present study, we aimed to develop a population PK model of sufentanil in ECMO patients and identify covariates associated with sufentanil exposure in order to suggest a more rational dosing recommendation.
Methods
Study design and ethics approval
This was a prospective, cohort study conducted at the cardiac intensive care unit in Severance Cardiovascular Hospital, a university-affiliated tertiary care hospital in Seoul, Republic of Korea, between January 2016 and June 2017. The study was approved by the Institutional Review Board (IRB No.: 4-2014-0919) of Severance Hospital and was registered at Clinicaltrials.gov (NCT02581280). Written informed consent was obtained from the patients or the legal surrogates of unconscious patients. This study complied with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE).
Study population
Twenty patients aged 19 years or older, who received sufentanil-based analgesia and sedation during VA-ECMO, were enrolled in this study. The exclusion criteria were younger than 19 years, known allergy to sufentanil, and taking any medication that could cause potential drug-drug interactions or alter sufentanil concentrations.
Dosing, administration, and data collection
ECMO patients received sufentanil for maintenance of analgesia and sedation supplemented as needed with midazolam. Sufentanil dosing in our centre was based on patients’ body weight, with initial infusion doses of 12.5 (< 60 kg) or 17.5 μg h−1 (≥60 kg). An initial bolus of 3 (< 60 kg) or 5 mg (≥ 60 kg) midazolam was given, with an initial infusion dose of 4.5 mg h−1. Management of pain should be guided by routine pain assessment of Nonverbal Pain Scale. Nurses assessed the depth of sedation, indicating the prevalent Richmond Agitation Sedation Scale (RASS) in their work shift. Analgesia and sedation protocol was to keep patients deeply sedated during the first few days of ECMO followed by intermediate or light sedation before ECMO discontinuation when possible. The infusion rates of sufentanil and midazolam were modified to achieve a target RASS score, and each dose adjustment was recorded.
Data on demographics, organ function, ECMO, vital signs, and drug dosing were collected from the electronic medical records.
The ECMO circuit included a centrifugal blood pump with a pump controller (Capiox® SP-101, Terumo Inc., Tokyo, Japan), an air-oxygen mixer (Sechrist® Ind., Anaheim, CA, USA), and conduit tubing (Capiox® EBS Circuit with X coating, Terumo Inc.). The days on ECMO, ECMO flow rate, and ECMO pump speed were recorded.
Sample collection and plasma concentration assay
The study was initiated during the first 48 h of starting ECMO. Blood samples were collected after 3 and 12 h of infusion and then every 24 h until 96 h had elapsed. When infusion was discontinued for any reason, blood was sampled after 0, 0.5, 1, 2, 6, and 12 h, and then every 24 h until 72 h had elapsed. Each blood sample (2 mL) was drawn from an existing arterial line and collected in a tube containing ethylenediaminetetraacetic acid as an anticoagulant. The blood samples were centrifuged at 1500×g for 10 min at 4 °C, and the plasma was immediately stored at − 80 °C until needed.
The plasma concentrations of sufentanil were analysed using a validated HPLC system (Agilent Technologies, CA, USA) coupled with a 4000 Qtrap liquid chromatograph-mass spectrometer (ASICX, Concord, Ontario, Canada). The plasma samples were denatured with acetonitrile containing 0.5 μg mL−1 prazosin as an internal standard. The mixture was vortexed and centrifuged at 150,000×g for 10 min at 4 °C. HPLC was performed on a Kinetex C18 analytical column (4.6 × 50 mm; particle size 2.6 μm; Phenomenex, Torrance, CA, USA) with a mobile phase consisting of 0.1% formic acid in acetonitrile at a flow rate of 0.055 mL min−1. The lower limit of quantification for sufentanil was 0.02 μg L−1. The assay was validated between 0.02 and 10 μg L−1 with inter- and intra-assay coefficients of variation of < 15%.
Population PK model development
The population PK model was developed using a first-order conditional estimation method with an interaction (FOCE+I) algorithm in the nonlinear mixed effects modelling software NONMEM® version 7.4 (ICON Development, Ellicott City, MD, USA). Pirana® ver. 2.9.2 and Xpose® ver. 4.0 (
http://xpose.sourceforge.net) in R® ver. 3.2.4 (
http://www.r-project.org) were used to visualise and evaluate the models. One-, two-, and three-compartment models were evaluated as the structural PK models. Inter-individual variability (IIV) for the PK parameters was modelled assuming a log-normal distribution:
θi =
θPop × EXP(
ηi), where
θi is the individual value of the parameter
θ in the
ith individual,
θPop is the population value of this parameter, and
ηi is a random variable with mean zero and variance
ωη2 [
18]. Proportional models for residual variability was used:
cij =
cpij × (1 +
εij) in which
cij is the
jth observed concentration of the
ith individual,
cpij is the corresponding predicted concentration, and
εij is a random variable with mean zero and variance
σ2.
The likelihood ratio test was used to evaluate statistical significance between nested models where a decrease in the objective function value (OFV), a statistical equivalent to the − 2 log likelihood of the model, of at least 3.84 was considered statistically significant for an added parameter (
χ2 distribution, degrees of freedom (df) = 1,
p < 0.05). In addition, bias of the goodness-of-fit plots (observed versus population predicted concentrations, observed versus individual predicted concentrations, conditional weighted residuals (CWRES) versus population predicted concentrations, and CWRES versus time after dosing), visual improvement of individual plots, confidence intervals of parameter estimates, and shrinkage were assessed. The aim of this study was to examine the potential effect of various covariates of the model structural parameters. The following covariates were investigated: sex, age, weight, lean body weight, body mass index, tympanic body temperature, total plasma protein, partial pressure of carbon dioxide, plasma pH, estimated glomerular filtration rate, serum creatinine, total bilirubin, alanine transaminase, aspartate transaminase, use of continuous renal replacement therapy, ECMO pump speed, and ECMO flow rate. The estimated parameters were plotted against each covariate to identify its influence. Continuous covariates (Cov) were incorporated into the structural model with centering on their median values within the population and tested using power (1), linear (2), and exponential (3) equations:
$$ {\theta}_{\mathrm{Pop}}={\theta}_{\mathrm{TV}}\times {\left\{\mathrm{Cov}/\mathrm{Median}\left(\mathrm{Cov}\right)\right\}}^{\theta_{\mathrm{Cov}}} $$
(1)
$$ {\theta}_{\mathrm{Pop}}={\theta}_{\mathrm{TV}}+{\theta}_{\mathrm{Cov}}\times \left\{\mathrm{Cov}-\mathrm{Median}\left(\mathrm{Cov}\right)\right\} $$
(2)
$$ {\theta}_{\mathrm{Pop}}={\theta}_{\mathrm{TV}}\times \mathrm{EXP}\left({\theta}_{\mathrm{Cov}}\times \mathrm{Cov}/\mathrm{Median}\left(\mathrm{Cov}\right)\right) $$
(3)
where
θTV is the typical value of the parameter and
θCov quantifies the covariate effect. The covariate model building was carried out in a stepwise process. In the forward selection, a
P value of < 0.05 was used (a decrease in OFV of at least 3.84, df = 1), while in the backward elimination, a
P value of < 0.01 was applied (a decrease in the OFV of at least 6.64, df = 1).
Model evaluation and simulations
To evaluate stability in the final model, a non-stratified bootstrap analysis was performed using the PsN Toolkit [
19]. A bootstrap with 5000 runs was performed on the final model to evaluate the internal validity of the parameter estimates and their corresponding 95% confidence intervals (CIs). The model performance was evaluated by means of prediction-corrected visual predictive checks (pc-VPCs). One thousand datasets were simulated from the final model, and the median and 90% CI of the simulated data were plotted along with the observed concentrations. To illustrate the effect of body temperature and total plasma protein level on predicted sufentanil concentrations, Monte Carlo simulations were performed using PK parameters from the final model. We assumed that sufentanil was continuously infused for 120 h with a rate of 12.5 or 17.5 μg h
−1, which were the doses most frequently used in our ECMO patients. The median parameter values for the patient population were obtained with five different levels of body temperature (33, 35, 36.7, 38 and 39 °C) and four different total plasma protein levels (2, 4, 6, and 8 g dL
−1) by simulating 1000 individuals in each case.
Discussion
We analysed a population of 20 critically ill ECMO patients who received sufentanil-based analgesia and sedation, and we described a population PK model. A two-compartment model with first-order elimination fitted the time course of the total plasma sufentanil concentrations best. In our final model, increased Vd (V1, 229 L; V2, 1640 L, standardised total plasma protein level of 4.5 g dL
−1) and decreased values for clearance (CL, 37.8 L h
−1, standardised temperature of 36.9 °C;
Q, 41 L h
−1) were reported compared with previous PK data from non-critically ill patients (V1, 37.1 L; V2, 92.7 L; CL, 76.2 L h
−1;
Q, 52.2 L h
−1) [
20] and critically ill patients not undergoing ECMO (Vd, 1582 L; CL, 56 L h
−1) [
21]. Sufentanil, as a highly lipophilic (logP = 3.24) and high protein-binding (91–93%) drug [
22], could be largely sequestered in the ECMO circuit, which mimics an increase in Vd [
15]. Moreover, a systemic inflammatory response, which can be triggered by the patient’s clinical condition or the initiation of ECMO, alters permeability of the blood-brain barrier and impacts the Vd of sufentanil [
13]. Decreased CL may have resulted from the reduced hepatic blood flow and impaired hepatic function in critically ill patients [
23]. Although nine patients received CVVHDF concomitantly with ECMO, it would have little effect on sufentanil PK. Primary mechanism of sufentanil clearance is the liver. Also, the drug is lipophilic, exhibits highly protein binding, and has a relatively high molecular weight (386.552 g/mol). Thus, it is expected that sufentanil would not be removed by CVVHDF, with limited clearance by VA-ECMO.
Body temperature and total protein level were found to be significant covariates of sufentanil PK, and interestingly, weight-related covariates were not included in the final model. In previous sufentanil PK studies in patients undergoing coronary artery bypass surgery, adding weight as a covariate showed neither a significant change in log-likelihood nor an improvement in predictive ability due to the large impact of coronary artery bypass surgery on sufentanil PK [
16,
24]. Since ECMO also has a large impact on sufentanil PK, we concluded that body weight is rendered insignificant as a factor in our final model.
The relationship between body temperature and sufentanil systemic clearance was described as follows: CL = 37.8 × EXP (0.207 × (temperature − 36.9)) L h
−1. These results are in agreement with the findings of previous studies, in which sufentanil showed decreased clearance in hypothermic patients [
25‐
27]. There are several processes that may be responsible for a decrease in sufentanil CL as body temperature drops. Sufentanil, a drug with a high liver-extraction ratio (hepatic extraction ratio of 0.7), is expected to be sensitive to blood flow alterations [
11]. When body temperature drops, total hepatic blood flow is assumed to be markedly reduced [
28], which then reduces the hepatic elimination of sufentanil. Furthermore, sufentanil metabolism occurs mainly via the cytochrome P450 system (CYP450), which is known to be strongly affected by temperature. Low temperature changes the binding pocket confirmation of CYP3A4, which reduces substrate affinity for CYP3A4 binding sites and slows CYP3A4 metabolic activity [
29]. In recent studies, CYP3A4*1G genetic polymorphism was found to be correlated with a lower amount of sufentanil consumption due to impaired activity of CYP3A4 [
30,
31]. The frequency of the CYP3A4*1G variant allele showed big difference by ethnicity, which was 0.188–0.279 in Chinese patients [
32] and 0.079 in Caucasian patients [
33]. In further studies, CYP3A4 polymorphism should be considered when extrapolating our data to other patient groups.
The effect of temperature is especially relevant in ECMO patients who show variability in body temperature for many reasons. The body temperature of ECMO patients could drop because of repeated blood transfusion, infusion of fluid, severe infection, and sepsis. In addition, to minimise brain damage, the body temperatures of ECMO patients after cardiac arrest are not allowed to exceed 36 °C over 24 h. In contrast, some ECMO patients could develop fever, which is associated, for example, with inflammation, elevated sympathetic tone, and catheter-related infections.
We also found that total plasma protein level was correlated positively with V2. Our results are different from those of other studies, in which total protein level was negatively correlated with V2 [
34‐
36]. One teicoplanin PK study demonstrated that a reduction in protein binding due to hypoproteinaemia could promote the distribution of the free form of teicoplanin into extravascular or intracellular spaces, thus increasing the volume of distribution [
35]. However, our finding could be explained by the fact that sufentanil binding is affected mainly by the plasma concentration of α1-acid glycoprotein, and not by the total plasma protein level. Low total protein levels might reflect impaired hepatic function, which could produce low apparent volumes of distribution [
37]. We want to highlight that our results are observatory and further studies are needed to fully uncover the relationship between total protein level and volume of distribution. Furthermore, our estimates of V2 shrinkage were relatively high (33%), so these estimates should be interpreted with caution.
Targeted sufentanil plasma concentrations in critically ill patients have not yet been determined accurately with PK/pharmacodynamic studies. Pain and sedation management are important consideration in the care of the ECMO patients, and no practice guidelines exist for this population. Recent evidences suggest sedative/analgesic protocols aiming for minimal and lighter sedation to improve clinical outcomes [
38,
39]. With limited data in patients with cardiac surgery together [
40‐
43], we suggested a target concentration between 0.3 and 0.6 μg mL
−1 to ensure sedation and better clinical outcomes. Overall, an infusion of 17.5 μg h
−1 seems better than 12.5 μg h
−1 in most ECMO patients, except hypothermia patients (33 °C). In hypothermic patients, over-sedation, which could induce respiratory depression, needs to be monitored especially when their total plasma protein level is low. With assessment of the analgesia and sedative levels, dose reductions should be considered. On the contrary, optimal levels of analgesia and sedation could not be induced with commonly used doses in hyperthermic patients, which suggests that an increased dose should be considered.
Our study did have several limitations. First, although the hepatic clearance of sufentanil is largely dependent on hepatic plasma flow, we did not observe hepatic blood flow as a potential covariate of CL in our PK model. Second, the concomitant use of sedating and paralysing medications prevented us from exploring the pharmacodynamics of sufentanil in terms of the level of sedation and analgesia. Future prospective studies that control for the presence of concomitant sedating and paralysing agents and that measure the exact degree of sedation and analgesia score are needed to link drug concentrations to the level of sedation and analgesia to determine appropriate concentrations. Nevertheless, the model developed in our study could be used for future sufentanil dosing considerations and the design of clinical studies in patients using ECMO.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.